2. EntreMed ( ENMD) Company Profile: EntreMed is a pharmaceutical company that is looking to develop and commercialize drugs for the treatment of cancer and inflammatory diseases. Shares of EntreMed rose last Monday after the company announced it secured $10 million in financing. Later in the week, EntreMed rallied sharply after stakeholder Celgene ( CELG) announced it would acquire cancer drug maker Avila Therapeutics, which also develops kinase inhibitors. Share Price: $2.60 (Jan. 27) 2012 Total Return: 173% Analyst Ratings: No Wall Street firm currently has coverage of EntreMed. TheStreet Ratings has a "sell" rating on EntreMed.